Available Trials

A randomized, multicenter, double blind Phase 3 study of PD-0332991 (Oral CDK 4/6 inhibitor) plus letrozole versus placebo plus letrozole for the treatment of postmenopausal women with ER(+), HER2(-) breast cancer who have not received any prior systemic anti-cancer treatment for advanced disease.

• Bladder
• Breast
• Colon
• Gastrointestinal
• Head and Neck
• Hematology
• Hepatic
• Leukemia
• Lung
• Lymphoma
• Melanoma
• Myelomas
• Ovarian
• Pancreatic
• Prostate
• Renal
• Solid Tumors

 

Bladder

• Phase I/II Study of Enfortumab Vedotin in Urothelial Cancer

  A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer
  

  ---

• Phase 3 Study of Infigratinib in Urothelial Carcinoma

  Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations
  

  ---

• Phase 2 Study of Sitravatinib with PD-L1 Checkpoint Inhibitor in Urothelial Cancer

  A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma
  

  ---

• Phase 3 Study of Erdafitinib in Urothelial Cancer

  A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations
  

  ---

• IMMU-132 for Metastatic Urothelial Cancer

  A Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy (IMMU-132-06)
  

  ---

Breast

• Phase I/II trial of Ibrutinib plus Trastuzumab in HER2-amplified Metastatic Breast Cancer

  Phase I/II trial of Ibrutinib plus Trastuzumab in HER2-amplified Metastatic Breast Cancer
  

  ---

• Phase 1/2 Study of CT7001 + Fulvestrant in Her2 Negative Breast Cancer Patients

  A Phase 1/2 Study of CT7001 in Combination with Fulvestrant in Patients with Metastatic or Locally Advanced Hormone-Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
  

  ---

• Phase 1a/1b Study of LY3484356 in Metastatic Breast Cancer Patient

  A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination with Anticancer Therapies for Patients with ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers
  

  ---

• Phase I Study of D-0502 +/- Palbociclib in Her2 Negative Breast Cancer

  A Phase I, Open-Label Study of D-0502 Single Agent and D-0502 in Combination with Palbociclib in Women With Advanced or Metastatic ER- Positive and HER2-Negative Breast Cancer
  

  ---

• Phase 2 of Tucatinib in Combination with Trastuzumab Deruxtecan

  A Single Arm, Open Label Phase 2 Study of Tucatinib in Combination with Trastuzumab Deruxtecan in Subjects with Previously Treated Unresectable Locally-Advanced or Metastatic HER2+ Breast Cancer
  

  ---

• Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab

  Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer
  

  ---

Colon

• Phase 2 Study of Tucatinib in Colorectal Cancer

  A Phase 2, Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer
  

  ---

• Phase 3 Study of Olaparib in Metastatic Colorectal Cancer Patients

  A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Bevacizumab Compared to Bevacizumab With 5-FU in Participants with Unresectable or Metastatic Colorectal Cancer who Have not Progressed Following First-line Induction of FOLFOX With Bevacizumab
  

  ---

• Phase 3 Trilaciclib/Placebo in Metastatic Colorectal Cancer

  A Phase 3 Randomized, Double-blind Trial of Trilaciclib versus Placebo in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer
  

  ---

• Phase 3b for MSI-H or MMR Colorectal Cancer Patients

  A Phase 3b Randomized Clinical Trial of Nivolumab Alone, or in Combination with Ipilimumab, or an Investigator’s Choice Chemotherapy in Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic Colorectal Cancer
  

  ---

Gastrointestinal

• Phase 3 Study of INCMGA00012 in Anal Cancer

  A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy
  

  ---

• Phase 3 Study of Sintilimab in Esophageal Cancer

  A Multicenter, Double-Blind, Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo, in Combination with Chemotherapy, for First-Line Treatment of Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma
  

  ---

• Phase 3 Study of Infigratinib vs. Gemcitabine with Cisplatin in Cholangiocarcinoma

  A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations
  

  ---

• Phase 3 Study of Pembrolizumab in 1st Line Biliary Tract Carcinoma

  A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants with Advanced and/or Unresectable Biliary Tract Carcinoma
  

  ---

• Chemotherapy +/- Pembrolizumab in 1st Line Her2- Gastric or GEJ cancer

  A Phase 3, randomized, double-blind clinical study of pembrolizumab (MK-3475) plus chemotherapy versus placebo plus chemotherapy as first-line treatment in participants with HER2 negative, previously untreated, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma
  

  ---

• Trastuzumab/Chemotherapy +/- Pembrolizumab in 1st Line Her2+ Gastric or GEJ Cancer

  A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab Plus Chemotherapy and Placebo as First-line Treatment in Participants With HER2 Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
  

  ---

Head and Neck

• Phase 3 Study of Pembrolizumab +/- lenvatinib in Recurrent or Metastatic Head and Neck Cancer

  
  

  ---

• Phase 3 Study of Avasopasem Manganese in Metastatic Head and Neck Cancer

  Reduction in Oral Mucositis with Avasopasem Manganese (GC4419)- Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer
  

  ---

Hematology

• Phase 3 Study of Navitoclax in Myelofibrosis

  A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Ruxolitinib in Subjects with Myelofibrosis
  

  ---

• Phase 3 Study of Pacritinib in Severe Thrombocytopenia

  A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia
  

  ---

Hepatic

• Phase 2 Study of MK-1308A + Lenvatinib in First Line Hepatocellular Cancer

  A Phase 2, Multicenter, Clinical Study to Evaluate the Safety and Efficacy of MK-1308A (MK1308/MK3475) in Combination with Lenvatinib (E7080/MK7902) in First-line Therapy of Participants with Advanced Hepatocellular Carcinoma
  

  ---

Leukemia

• Phase 3 Study of LOXO-305 in CLL/SLL Patients

  A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  

  ---

• Phase 2 Study of Ublituximab in Combination with Umbralisib and Venetoclax for CLL patients

  Phase 2 Study to Assess the Efficacy and Safety of Ublituximab in Combination with Umbralisib and Venetoclax (U2-V) in Subjects with Chronic Lymphocytic Leukemia
  

  ---

• Phase III of Obinutuzumab and Venetoclax in Untreated CLL without 17p deletion or Tp53 mutation

  A PROSPECTIVE, OPEN-LABEL, MULTICENTER RANDOMIZED PHASE III TRIAL TO COMPARE THE EFFICACY AND SAFETY OF A COMBINED REGIMEN OF OBINUTUZUMAB AND VENETOCLAX VERSUS FLUDARABINE, CYCLOPHOSPHAMIDE AND RITUXIMAB (FCR)/ BENDAMUSTINE AND RITUXIMAB (BR) IN FIT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITHOUT DEL (17P) OR TP53 MUTATION
  

  ---

Lung

• Phase 2 Study of VS-6766 +/- Defactinib in Lung Cancer

  A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) as a Single Agent and in Combination with Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) Non-Small Cell Lung Cancer
  

  ---

• Phase 3 Study of MRTX849 in Lung Cancer

  A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation
  

  ---

• Phase 3 Study of Amivantamab and Lazertinib in Lung Cancer

  A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
  

  ---

• Phase 3 Study of Amivantamab in Lung Cancer

  A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
  

  ---

• Phase 3 Study of Pralsetinib in Lung Cancer

  A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer
  

  ---

• Phase 3 Study of Brigatinib in Lung Cancer

  A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib
  

  ---

• Phase 2 Study of AB122 and AB154 in Front Line Non-Small Cell Lung Cancer Patients

  A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination with AB122, and AB154 in Combination with AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer
  

  ---

• Phase 1/2 Study of NKTR-214 in Patients with Locally Advanced/Metastatic Solid Tumors

  
  

  ---

• Phase III Study of Tiragolumab in Stage III Non-Small Cell Lung Cancer Patients

  A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB AND TIRAGOLUMAB COMPARED WITH DURVALUMAB IN PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER WHO HAVE NOT PROGRESSED AFTER CONCURRENT PLATINUM-BASED CHEMORADIATION
  

  ---

• Phase III Study of Tiragolumab in patients with Small Cell Lung Cancer

  A Phase III, Randomized, Double-Blind, Placebo-controlled study of Atezolizumab plus Carboplatin and Etoposide with or without Tiragolumab (Anti-Tigit Antibody) in patients with untreated extensive-stage small cell lung cancer
  

  ---

• Phase III Study of Atezolizumab in Combination with Cabozantinib for previously treated Lung Cancer

  A Phase III, Multicenter, Randomized, Open-Label, Controlled Study To Evaluate the Efficacy, Safety, and Pharmacokinetics of Atezolizumab given in combination with Cabozantinib versus Docetaxel Monotherapy in Patients with Metastatic Non Small Cell Lung Cancer Previously Treated With an Anti PD-L1/PD-1 Antibody And Platinum-Containing Chemotherapy
  

  ---

• Phase 2 Study of Telaglenastat in 1st line Metastatic KEAP/NRF-2 mutated Non-Small Cell Lung Cancer

  A Phase 2, Randomized, Multicenter, Double-blind, Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy versus Placebo with Pembrolizumab and Chemotherapy in First-line Metastatic KEAP1/NRF2-mutated Nonsquamous, Non-Small Cell Lung Cancer
  

  ---

• Phase 3 Study of Tiragolumab in PD-L1 Selected Non-Small Cell Lung Cancer Patients

  A Phase III, Randomized, Double-Blinded, Placebo-Controlled Study of Tiragolumab, an anti-TIGIT antibody, in combination with Atezolizumab compared with Placebo in combination with Atezolizumab in patients with previously untreated locally advanced unresectable or metastatic PD-L1 selected Non-Small Cell Lung Cancer
  

  ---

• Canakinumab for Adjuvant Non-Small Cell Lung Cancer

  A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer
  

  ---

Lymphoma

• Phase 2b Study of Ublituximab in Patients with Previously Treated Non-Hodgkins Lymphoma

  A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + Umbralisib with or without Bendamustine and Umbralisib alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
  

  ---

• Phase 3 Study of Acalabrutinib in Untreated Diffuse Large B-Cell Lymphoma

  A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects < or = 65 Years with Previously Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma
  

  ---

• Phase 1b/3 Study of Taxemetostat for Relapsed/Refractory Follicular Lymphoma

  A PHASE 1B/3 DOUBLE-BLIND, RANDOMIZED, ACTIVE-CONTROLLED, 3-STAGE, BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA
  

  ---

• Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects

  Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
  

  ---

• Brentuximab Vedotin in combination with Nivolumab for Hodgkins Lymphoma

  A phase 2 open-label study of Brentuximab Vedotin in combination with Nivolumab in front-line therapy of Hodgkin Lymphoma (HL) in adults age 60 and above
  

  ---

• Rituximab +/- Ibrutinib for Follicular Lymphoma

  A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma
  

  ---

Melanoma

• Phase 3 Study of Adjuvant Immunotherapy in Melanoma Patients

  A Phase 3, Randomized, Open-label Study of Adjuvant Immunotherapy with Bempegaldesleukin with Nivolumab Versus Nivolumab after Complete resection of Melanoma in Participants at High Risk for Recurrence
  

  ---

Myelomas

• Phase II Study for 1st or 2nd Relapse of Multiple Myeloma

  An Open-label, Phase 2 Study Treating Subjects With First or Second Relapse of Multiple Myeloma with Carfilzomib, Pomalidomide, and Dexamethasone
  

  ---

Ovarian

• Phase 2 Study ofVS-6766 +/- Defactinib in Ovarian Cancer

  A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer
  

  ---

Pancreatic

• Phase 2 Study of SBRT with GC4711 for Unresectable, Non-Metastatic Pancreatic Cancer

  A Randomized, Phase 2 Study of Stereotactic Body Radiation Therapy (SBRT) in combination with GC4711 in the Treatment of Unresectable or Borderline Resectable, Nonmetastatic Pancreatic Cancer
  

  ---

• Phase III Study of Irinotecan Lipsome Injection in Pancreatic Patients

  An open-label, randomised, multicentre, phase III study of irinotecan liposome injection, oxaliplatin, 5-fluorouracil/leucovorin versus nab-paclitaxel plus gemcitabine in subjects who have not previously received chemotherapy for metastatic adenocarcinoma of the pancreas
  

  ---

• Tumor Treating Fields with Gemzar/Nab-Paclitaxel for Pancreatic Cancer

  Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma (EF-27)
  

  ---

Prostate

• Phase 3 Study of Niraparib in Prostate Cancer

  A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer
  

  ---

• Phase 3 of Rucaparib vs. Physician Choice in Prostate Cancer

  A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency
  

  ---

• Phase 3 Study of Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer

  A Phase 3, Randomized, Double-blind Study of Pembrolizumab (MK-3475) Plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone in Participants with Chemotherapy-naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC) who have Progressed on a Next Generation Hormonal Agent (NHA)
  

  ---

• Phase 1b Study of Cabozantinib +/- Atezolizumab in Locally Advanced or Metastatic Solid Tumors

  A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors
  

  ---

• Enzalutamide +/- Pembrolizumab in Prostate Cancer

  A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
  

  ---

Renal

• Phase 2 Study of MK-6482 in Renal Cell Patients

  Phase 2 Study of MK-6482 in Participants With Advanced Renal Cell Carcinoma
  

  ---

• Phase 3 Study of MK-6482 with Lenvatinib for Metastatic Renal Cell Cancer Patients

  An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After 1 Prior Anti-PD-1/L1 Combination Regimen
  

  ---

Solid Tumors

• Phase 2 Study of Tucatinib with Trastuzumab in Solid Tumors

  A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated, Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations
  

  ---

• Phase 2 Study of Seribantumab in Solid Tumors

  A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors
  

  ---

• Phase 2 Study of AK104 in Cervical Cancer

  A Phase 2, multicenter, single-arm, open-label study to evaluate the efficacy and safety of AK104 in subjects with recurrent or metastatic cervical cancer
  

  ---

• Phase 2 Study of Erdafitinib in Solid Tumors

  A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations
  

  ---

• Phase 2 Study of Pemigatinib in Solid Tumors

  A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations
  

  ---

• Cabozanitib +/- Atezolizumab in Solid Tumors

  A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors
  

  ---